Local Knowledge Coupled With Extensive Partnerships Required For Asia Success: BioMedical Asia 2008
SINGAPORE - Recreating existing business models in Asia will likely not be successful in the long run, panelists concurred at the Biomedical Asia 2008 conference held in Singapore, April 15-17. In fact, what may make or break a company will be its capacity to collaborate in a system of multiple vendors in an extreme outsourcing environment
More from Archive
More from Scrip
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
While diverging from partner Merck & Co. in its study dosage of sacituzumab tirumotecan, Kelun has garnered the world’s first approval, in China, for a TROP2-targeting antibody-drug conjugate, for the treatment of lung cancer.
With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.